Profiling the Genetic and Molecular Characteristics of Glanzmann Thrombasthenia: Can It Guide Current and Future Therapies?

References

• Caen JP, Castaldi PA, Leclerc JC, et al. Congenital bleeding disorders with long bleeding time and normal platelet count. I. Glanzmann’s thrombasthenia (Report of 15 patients). Am J Med. 1966;41(1):4–26. doi:10.1016/0002-9343(66)90003-9
   Web of Science ®Google Scholar
• George JN, Caen JP, Nurden AT. Glanzmann thrombasthenia: the spectrum of clinical disease. Blood. 1990;75(7):1383–1395.
   PubMed Web of Science ®Google Scholar
• Bellucci S, Caen J. Molecular basis of Glanzmann’s thrombasthenia and current strategies in treatment. Blood Rev. 2002;16(3):193–202. doi:10.1016/S0268-960X(02)00030-9
   PubMed Web of Science ®Google Scholar
• Nurden AT, Caen JP. An abnormal platelet glycoprotein in three cases of Glanzmann’s thrombasthenia. Br J Haematol. 1974;28(2):233–253. doi:10.1111/j.1365-2141.1974.tb06660.x
   Web of Science ®Google Scholar
• Phillips DR, Agin PP. Platelet membrane defects in Glanzmann’s thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest. 1977;60(3):535–545. doi:10.1172/JCI108805
   PubMed Web of Science ®Google Scholar
• Hagen I, Nurden A, Bjerrum OJ, Solum NO, Caen J. Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann’s thrombasthenia and Bernard-Soulier syndrome. J Clin Invest. 1980;65(3):722–731. doi:10.1172/JCI109719
   Web of Science ®Google Scholar
• Kunicki TJ, Pidard D, Rosa JP, Nurden AT. The formation of Ca2+-dependent complexes in solution as determined by crossed immunoelectrophoresis. Blood. 1981;58(2):268–278. doi:10.1182/blood.V58.2.268.268
   Web of Science ®Google Scholar
• Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists and even a bend. Blood. 2008;112(8):3011–3025. doi:10.1182/blood-2008-06-077891
   PubMed Web of Science ®Google Scholar
• Carrell NA, Fitzgerald LA, Steiner B, Ericksen HP, Phillips DR. Structure of human platelet membrane glycoproteins IIb and IIIa as determined by electron microscopy. J Biol Chem. 1985;260(3):1743–1749. doi:10.1016/S0021-9258(18)89656-9
   Web of Science ®Google Scholar
• Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004;432(7013):59–67.
   PubMed Web of Science ®Google Scholar
• Fitzgerald LA, Steiner B, Rall SC Jr, Lo SS, Phillips DR. Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarly to “integrin”. J Biol Chem. 1987;262(9):3936–3939. doi:10.1016/S0021-9258(18)61290-6
   Web of Science ®Google Scholar
• Thornton MA, Poncz M, Korostishevsky M, et al. The human platelet alphaIIb gene is not closely linked to its integrin partner beta3. Blood. 1998;94(6):2039–2047. doi:10.1182/blood.V94.6.2039
   Web of Science ®Google Scholar
• Newman PJ, Seligsohn U, Lyman S, Coller BS. The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci USA. 1991;88(8):3160–3164. doi:10.1073/pnas.88.8.3160
   Web of Science ®Google Scholar
• French DL, Coller BS. Hematologically important mutations: glanzmann thrombasthenia. Blood Cells Mol Dis. 1997;23(3):39–51. doi:10.1006/bcmd.1997.0117
   Web of Science ®Google Scholar
• Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011;118(23):5996–6005. doi:10.1182/blood-2011-07-365635
   PubMed Web of Science ®Google Scholar
• Nurden AT, Pillois X. ITGA2B and ITGB3 gene mutations associated with Glanzmann thrombasthenia. Platelets. 2018;29(1):98–101. doi:10.1080/09537104.2017.1371291
   PubMed Web of Science ®Google Scholar
• Nurden AT, Pillois X, Fiore M, et al. Expanding the mutation spectrum affecting αIIbβ3 integrin in Glanzmann thrombasthenia: screening of the ITGA2B and ITGB3 genes in a large international cohort. Hum Mutat. 2015;36(5):548–561. doi:10.1002/humu.22776
   PubMed Web of Science ®Google Scholar
• Coller BS, Seligsohn U, West SM, Scudder LE, Norton KJ. Platelet fibrinogen and vitronectin in Glanzmann thrombasthenia: evidence consistent with specific roles for glycoprotein IIb/IIIa and alphavbeta3 integrins in platelet protein trafficking. Blood. 1991;78(10):2603–2610. doi:10.1182/blood.V78.10.2603.2603
   PubMed Web of Science ®Google Scholar
• Nurden AT. Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses? Blood Rev. 2017;31(5):287–299. doi:10.1016/j.blre.2017.03.005
   Web of Science ®Google Scholar
• De Cuyper IM, Meinders M, van de Vijver E, et al. A novel flow cytometry-based platelet aggregation assay. Blood. 2013;121(10):e70–e80. doi:10.1182/blood-2012-06-437723
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063–2065. doi:10.1111/j.1538-7836.2010.03975.x
   PubMed Web of Science ®Google Scholar
• Schlegel N, Gayet O, Morel-Kopp M-C, et al. The molecular genetic basis of Glanzmann’s thrombasthenia I a gypsy population in France: identification of a new mutation on the αIIb gene. Blood. 1995;86(3):977–982. doi:10.1182/blood.V86.3.977.977
   PubMed Web of Science ®Google Scholar
• Kannan M, Ahmad F, Yadav BK, Kumar R, Choudhry VP, Saxena R. Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia. J Thromb Haemost. 2009;7(11):1878–1885. doi:10.1111/j.1538-7836.2009.03579.x
   PubMed Web of Science ®Google Scholar
• Farsinejad A, Farajollahi MM, Kazemi A, Saemi N, Faranoush M. Different biochemical expression pattern of platelet surface glycoproteins suggests molecular diversity of Glanzmann’s thrombasthenia in Iran. Blood Coagul Fibrinolysis. 2013;24(6):613–618. doi:10.1097/MBC.0b013e328360a558
   Web of Science ®Google Scholar
• Fiore M, Pillois X, Nurden P, Nurden AT, Austerlitz F. Founder effect and estimation of the age of the French gypsy mutation associated with Glanzmann thrombasthenia in Manouch families. Eur J Hum Genet. 2011;19(9):981987. doi:10.1038/ejhg.2011.61
   Web of Science ®Google Scholar
• Zhou L, Jiang M, Shen H, et al. Clinical and molecular insights into Glanzmann’s thrombasthenia in China. Clin Genet. 2018;94(2):213–220. doi:10.1111/cge.13366
   PubMed Web of Science ®Google Scholar
• Wilcox DA, Paddock CM, Lyman S, Gill JC, Newman PJ. Glanzmann thrombasthenia resulting from a single amino acid substitution between the second and third calcium-binding domains of GPIIb. J Clin Invest. 1995;95(4):1553–1560. doi:10.1172/JCI117828
   Web of Science ®Google Scholar
• Ferrer M, Fernandez-Pinel M, Gonzalez-Manchon C, Gonzalez J, Ayuso MS, Parrilla R. A mutant (Arg327->His) GPIIb associated to thrombasthenia exerts a dominant negative effect in stably transfected CHO cells. Thromb Haemost. 1996;76(3):292–301. doi:10.1055/s-0038-1650574
   Web of Science ®Google Scholar
• Grimaldi CM, Chen F, Wu C, Weiss HJ, Coller BS, French DL. Glycoprotein IIb Leu214Pro mutation produces Glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa. Blood. 1998;91(5):1562–1571. doi:10.1182/blood.V91.5.1562
   Web of Science ®Google Scholar
• Ambo H, Kamata T, Handa M, et al. Novel point mutations in the αIIb subunit (Phe289->Ser, Glu324->Lys, Gly747Pro) causing thrombasthenic phenotypes in four Japanese patients. Br J Haematol. 1998;102(3):829–840. doi:10.1046/j.1365-2141.1998.00824.x
   Web of Science ®Google Scholar
• Tadokoro S, Tomiyama Y, Honda S, et al. A Gln747->pro substitution in the αIIb subunit is responsible for a moderate αIIbβ3 deficiency in Glanzmann thrombasthenia. Blood. 1998;92(8):2750–2758. doi:10.1182/blood.V92.8.2750
   PubMed Web of Science ®Google Scholar
• Gonzalez-Manchon C, Fernandez-Pinel M, Arias-Salgado EG, et al. Molecular genetic analysis of a compound heterozygote for the glycoprotein (GP) IIb gene associated with Glanzmann’s thrombasthenia: disruption of the 674–687 disulfide bridge in GPIIb prevents surface exposure of GPIIb-IIIa complexes. Blood. 1999;93(3):866–875. doi:10.1182/blood.V93.3.866
   Web of Science ®Google Scholar
• Arias-Salgado EG, Butta N, Gonzalez-Manchon C, Larrucea S, Ayuso MS, Parrilla R. Competition between normal (674C) and mutant (674R)GPIIb subunits: role of the molecular chaperone BiP in the processing of GPIIb-IIIa complexes. Blood. 2001;97(9):2640–2647. doi:10.1182/blood.V97.9.2640
   Web of Science ®Google Scholar
• Basani RB, French DL, Vilaire G, et al. A naturally occurring mutation near the amino terminus of αIIb defines a new region involved in ligand binding to αIIbβ3. Blood. 2000;95(1):180–188. doi:10.1182/blood.V95.1.180
   Web of Science ®Google Scholar
• Kamata T, Tieu KK, Irie A, Springer TA, Takada Y. Amino acid residues in the αIIb subunit that are critical for ligand binding to integrin αIIbβ3 are clustered in the β-propeller model. J Biol Chem. 2001;276(47):44275–44283. doi:10.1074/jbc.M107021200
   Web of Science ®Google Scholar
• Mitchell WB, Li JH, Singh F, et al. Two novel mutations in the αIIb calcium-binding domains identify hydrophobic regions for αIIbβ3 biogenesis. Blood. 2003;101(6):22682276. doi:10.1182/blood-2002-07-2266
   Web of Science ®Google Scholar
• Jayo A, Pabon D, Lastres P, Jimenez V, Gonzalez-Manchon C. Type II Glanzmann thrombasthenia in a compound heterozygote for the αIIb gene. A novel missense mutation in exon 27. Haematologica. 2006;91(10):1352–1359.
   Web of Science ®Google Scholar
• Goguet M, Narwani TJ, Petermann R, Jallu V, de Brevern AG. In silico analysis of Glanzmann variants of Calf-1 domain of αIIbβ3 integrin revealed dynamic allosteric effect. Sci Rep. 2017;7(1):8001. doi:10.1038/s41598-017-08408-w
   Web of Science ®Google Scholar
• Pillois X, Peters P, Segers K, Nurden AT. In silico analysis of structural modifications in and around the integrin αIIb genu caused by ITGA2B variants in human platelets with emphasis on Glanzmann thrombasthenia. Mol Genet Genomic Med. 2018;6(2):249–260. doi:10.1002/mgg3.365
   Web of Science ®Google Scholar
• Grimaldi CM, Chen F, Scudder LE, Coller BS, French DL. A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (β3) in a Chinese patient with Glanzmann’s thrombasthenia. Blood. 1996;88(5):1666–1675. doi:10.1182/blood.V88.5.1666.1666
   Web of Science ®Google Scholar
• Ambo H, Kamata T, Handa M, et al. Three novel integrin β3 subunit missense mutations (H280P, C560F and G579S) in thrombasthenia, including one (H280P prevalent in Japanese patients. Biochem Biophys Res Commun. 1998;251(3):763–768. doi:10.1006/bbrc.1998.9526
   PubMed Web of Science ®Google Scholar
• Ward CN, Kestin AS, Newman PJ. A Leu262Pro mutation in the integrin β3 subunit results in an αIIbβ3 complex that binds fibrin but not fibrinogen. Blood. 2000;96(1):161–169. doi:10.1182/blood.V96.1.161
   PubMed Web of Science ®Google Scholar
• Nair S, Li J, Mitchell WB, Mohanty D, Coller BS, French DL. Two new beta3 integrin mutations in Indian patients with Glanzmann thrombasthenia: localization of mutations affecting cysteine residues in integrin beta3. Thromb Haemost. 2002;88(3):503–509. doi:10.1160/TH2002880503
   Web of Science ®Google Scholar
• Westrup D, Santoso S, Follert-Hagendorff K, et al. Glanzmann thrombasthenia Frankfurt I is associated with a point mutation Thr176Ile in the N-terminal region of αIIb subunit integrin. Thromb Haemost. 2004;92(5):1040–1051. doi:10.1160/TH04-03-0170
   Web of Science ®Google Scholar
• Morel-Kopp M-C, Melchior C, Chen P, et al. A naturally occurring point mutation in the β3 integrin MIDAS-like domain affects differently αvβ3 and αIIbβ3 receptor function. Thromb Haemost. 2001;86(6):1425–1434. doi:10.1055/s-0037-1616746
   Web of Science ®Google Scholar
• Chen P, Melchior C, Brons NHC, Schlegel N, Caen J, Kieffer N. Probing conformational changes in the I-like domain and the cysteine-rich repeat of human β3 integrins following disulfide bond disruption by cysteine mutations. Identification of cysteine 598 involved in αIIbβ3 activation. J Biol Chem. 2001;276(42):38628–38635. doi:10.1074/jbc.M105737200
   Web of Science ®Google Scholar
• Xiong JP, Stehle T, Diefenbach B, et al. Crystal structure of the extracellular segment of the integrin αvβ3. Science. 2001;294(5541):339–345. doi:10.1126/science.1064535
   PubMed Web of Science ®Google Scholar
• Takagi J, Petre B, Walz T, Springer TA. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 2002;110(5):599–601. doi:10.1016/S0092-8674(02)00935-2
   PubMed Web of Science ®Google Scholar
• Rosenberg N, Yatuv R, Sobolev V, Peretz H, Zivelin A, Seligsohn U. Major mutations in calf-1 and calf-2 domains of glycoprotein IIb in patients with Glanzmann thrombasthenia enable GPIIb/IIIa complex formation but impair its transport from the endoplasmic reticulum to the Golgi apparatus. Blood. 2003;101(6):4808–4815. doi:10.1182/blood-2002-08-2452
   Web of Science ®Google Scholar
• Gonzalez-Manchon C, Arias-Salgado EG, Butta N, et al. A novel homozygous splice junction mutation in GPIIb associated with alternative splicing, nonsense-mediated decay of GPIIb-mRNA, and type II Glanzmann’s thrombasthenia. J Thromb Haemost. 2003;1(5):1071–1078. doi:10.1046/j.1538-7836.2003.00204.x
   Web of Science ®Google Scholar
• Jackson DE, White MM, Jennings LK, Newman PJ. A Ser162->Leu mutation within glycoprotein (GP) IIIa (integrin αIIbβ3) results in an unstable αIIbβ3 complex that retains partial function in a novel form of type II Glanzmann thrombasthenia. Thromb Haemost. 1998;80(1):42–48. doi:10.1055/s-0037-1615136
   Web of Science ®Google Scholar
• Kiyoi T, Tomiyama Y, Honda S, et al. A naturally occurring Tyr143HisαIIb mutation abolishes αIIbβ3 function for soluble ligands but retains its ability for mediating cell adhesion and clot retraction: comparison with other mutations causing ligand-binding defects. Blood. 2003;101(9):3485–3491. doi:10.1182/blood-2002-07-2144
   Web of Science ®Google Scholar
• Flevaris P, Stojanovic A, Gong H, Chishti A, Welch E, Du X. A molecular switch that controls cell spreading and retraction. J Cell Biol. 2007;179(3):553–565. doi:10.1083/jcb.200703185
   Web of Science ®Google Scholar
• Loftus JC, O’Toole TE, Plow EF, Glass A, Frehlinger AL 3rd, Ginsberg MH. A β3 integrin mutation abolishes ligand binding and alters divalent-cation dependent conformation. Science. 1990;249(4971):915–918. doi:10.1126/science.2392682
   PubMed Web of Science ®Google Scholar
• Bajt ML, Ginsberg MH, Frelinger AL, Berndt MC, Loftus JC. A spontaneous mutation of integrin αIIbβ3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site. J Biol Chem. 1992;267(6):3789–3794. doi:10.1016/S0021-9258(19)50595-6
   Web of Science ®Google Scholar
• Lanza F, Stierle A, Fournier D, et al. A new variant of Glanzmann’s thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg->214Trp mutation. J Clin Invest. 1992;89(6):1995–2004. doi:10.1172/JCI115808
   Web of Science ®Google Scholar
• Honda S, Tomiyama Y, Shiraga M, et al. A two-amino acid insertion in the Cys146-Cys167 loop of the αIIb subunit is associated with a variant of Glanzmann thrombasthenia. J Clin Invest. 1998;102(6):1183–1192. doi:10.1172/JCI3206
   Web of Science ®Google Scholar
• Chen YP, Djaffar I, Pidard D, et al. Ser-752-Pro mutation in the cytoplasmic domain of integrin beta3 subunit and defective activation of platelet integrin alphaIIbbeta3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proc Natl Acad Sci USA. 1992;89(21):10169–10173. doi:10.1073/pnas.89.21.10169
   Web of Science ®Google Scholar
• Nurden P, Poujol C, Winckler J, Combrié R, Caen JP, Nurden AT. A Ser752->Pro substitution in the cytoplasmic domain of beta3 in a Glanzmann thrombasthenia variant fails to prevent interactions between the alphaIIbbeta3 integrin and the granule pool of fibrinogen. Br J Haematol. 2002;118(4):1143–1151. doi:10.1046/j.1365-2141.2002.03758.x
   Web of Science ®Google Scholar
• Wang R, Shattil SJ, Ambruso DR, Newman PJ. Truncation of the cytoplasmic domain of beta3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin alpha(IIb)beta3 complex. J Clin Invest. 1997;100(9):2393–2403. doi:10.1172/JCI119780
   Web of Science ®Google Scholar
• Vinogradova O, Velyvis A, Velyvienne A, et al. A structural mechanism of integrin alpha(IIb)beta(3) “inside-out” activation as regulated by its cytoplasmic face. Cell. 2002;110(5):587–597. doi:10.1016/S0092-8674(02)00906-6
   PubMed Web of Science ®Google Scholar
• Ruiz C, Liu C-Y, Sun Q-H, et al. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (αIIbβ3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood. 2001;98(8):2432–2441. doi:10.1182/blood.V98.8.2432
   Web of Science ®Google Scholar
• Mor-Cohen R, Rosenberg N, Peretz H, et al. Disulfide bond disruption by a β3-Cys549Arg mutation in six Jordanian families with Glanzmann thrombasthenia causes diminished production of constitutively active αIIbβ3. Thromb Haemost. 2007;98:1257–1265. doi:10.1160/TH07-04-0248
   PubMed Web of Science ®Google Scholar
• Kamata T, Ambo H, Puzon-McLaughin W, et al. Critical cysteine residues for regulation of integrin αIIbβ3 are clustered in the epidermal growth factor domains of the β3 subunit. Biochem J. 2004;378(3):1079–1082. doi:10.1042/bj20031701
   Web of Science ®Google Scholar
• Vanhoorelbeke K, De Meyer SF, Pareyn I, et al. The novel S527F mutation in the integrin β3 chain induces a high affinity αIIbβ3 receptor by hindering adoption of the bent conformation. J Biol Chem. 2009;284(22):14914–14920. doi:10.1074/jbc.M809167200
   Web of Science ®Google Scholar
• Gonzalez-Manchon C, Butta N, Larrucea S, et al. A variant thrombasthenic phenotype associated with compound heterozygosity of integrin β3-subunit (Met124Val)β3 alters the subunit dimerization rendering a decreased number of constitutive active αIIbβ3 receptors. Thromb Haemost. 2004;92(6):1377–1386. doi:10.1160/TH04-06-0380
   Web of Science ®Google Scholar
• Hardisty R, Pidard D, Cox A, et al. A defect of platelet aggregation associated with an abnormal distribution of glycoprotein IIb-IIIa complexes within the platelet: the cause of a lifelong bleeding disorder. Blood. 1992;80(3):696–708. doi:10.1182/blood.V80.3.696.696
   Web of Science ®Google Scholar
• Peyruchaud O, Nurden AT, Milet S, et al. An Arg995 ® to Gln (Q) aminoacid substitution in the GFFKR sequence of the cytoplasmic domain of the integrin IIb subunit in a patient with an unusual variant form of Glanzmann’s thrombasthenia. Blood. 1998;92(11):4178–4187. doi:10.1182/blood.V92.11.4178
   Web of Science ®Google Scholar
• Hughes PE, Diaz-Gonzalez F, Leong L, et al. Breaking the integrin hinge. A defined structural constraint regulates integrin signaling. J Biol Chem. 1996;271(12):6571–6574. doi:10.1074/jbc.271.12.6571
   PubMed Web of Science ®Google Scholar
• Kunishima S, Kashiwagi H, Otsu M, et al. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the alphaIIbbeta3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood. 2011;117(2):5479–5484. doi:10.1182/blood-2010-12-323691
   Web of Science ®Google Scholar
• Ghevaert C, Salamann A, Watkins NA, et al. A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation and the macrothrombocytopenia. Blood. 2008;111(7):3407–3414. doi:10.1182/blood-2007-09-112615
   PubMed Web of Science ®Google Scholar
• Favier M, Bordet J-C, Favier R, et al. Mutations of the αIIb/β3 intracytoplasmic salt bridge cause macrothrombocytopenia and enlarged platelet α-granules. Am J Haematol. 2017;93(2):195–204. doi:10.1002/ajh.24958
   Web of Science ®Google Scholar
• Morais S, Oliveira S, Lau C, et al. αIIbβ3 variants in ten families with autosomal dominant macrothrombocytopenia: expanding the mutational and clinical spectrum. PLoS One. 2020;15(12):e0235136. doi:10.1371/journal.pone.0235136
   Web of Science ®Google Scholar
• Gresele P, Falcinelli E, Giannini S, et al. Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica. 2009;94(5):663–669. doi:10.3324/haematol.2008.002246
   PubMed Web of Science ®Google Scholar
• Jayo A, Conde I, Lastres P, et al. L718P mutation in the membrane-proximal cytoplasmic tail of beta3 promotes abnormal alphaIIbbeta3 clustering and lipid domain coalescence and associates with a thrombasthenia-like phenotype. Haematologica. 2010;95(7):1158–1166. doi:10.3324/haematol.2009.018572
   Web of Science ®Google Scholar
• Nurden P, Bordet JC, Pillois X, Nurden AT. An intracytoplasmic β3 Leu718 deletion in a patient with a novel platelet phenotype. Blood Adv. 2017;1(8):494–499. doi:10.1182/bloodadvances.2016002808
   Web of Science ®Google Scholar
• Nurden AT, Nurden P. Inherited thrombocytopenias: history advances and perspectives. Haematologica. 2020;105(8):2004–2019. doi:10.3324/haematol.2019.233197
   Web of Science ®Google Scholar
• Nurden P, Stritt S, Favier R, Nurden AT. Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy. Haematologica. 2021;106(2):337–350. doi:10.3324/haematol.2020.248153
   PubMed Web of Science ®Google Scholar
• Peretz H, Rosenberg N, Landau M, et al. Molecular diversity of Glanzmanns thrombasthenia in Southern India: new insights into mRNA splicing and structure-function correlations of alphaIIbbeta3 integrin (ITGA2B, ITGB3). Hum Mutat. 2006;27(4):359–369. doi:10.1002/humu.20304
   PubMed Web of Science ®Google Scholar
• Nelson EJR, Nair SC, Peretz H, et al. Diversity of Glanzmann thrombasthenia in Southern India: 10 novel mutations identified among 15 unrelated patients. J Throm Haemost. 2006;4(8):1730–1737. doi:10.1111/j.1538-7836.2006.02066.x
   PubMed Web of Science ®Google Scholar
• Jallu V, Dusseaux M, Panzer S, et al. αIIbβ3 integrin: new allelic variants in Glanzmann thrombasthenia. Effects on ITGA2B and ITGB3 mRNA splicing, expression, and structure-function. Hum Mutat. 2009;31(3):237–246. doi:10.1002/humu.21179
   Web of Science ®Google Scholar
• Sandrock-Lang K, Oldenburg J, Wiegering V, et al. Characterization of patients with Glanzmann thrombasthenia and identification of 17 novel mutations. Thromb Haemost. 2015;113:782–791. doi:10.1160/TH14-05-0479
   Web of Science ®Google Scholar
• Robert P, Canault M, Farnarier C, et al. A novel leukocyte adhesion deficiency III variant: kindlin-3 deficiency results in integrin and non-integrin related defects in late steps of leukocyte adhesion. J Immunol. 2011;186(9):5273–5283. doi:10.4049/jimmunol.1003141
   Web of Science ®Google Scholar
• Desai A, Bergmeier W, Canault M, et al. Phenotype analysis and clinical management in a large family with a novel truncating mutation in RASGRP2, the CaLDAG-GEFI encoding gene. Res Pract Thromb Haemost. 2017;1(1):128–133. doi:10.1002/rth2.12019
   PubMed Web of Science ®Google Scholar
• Podolnikova NP, Gorkun OV, Loreth RM, Yee VC, Lord ST, Ugarova TP. A cluster of basic amino acid residues in the γ370–380 sequence of fibrinogen comprises a binding site for platelet integrin αIIbβ3 (GPIIb/IIIa). Biochemistry. 2005;44(51):1620–2630. doi:10.1021/bi051581d
   Web of Science ®Google Scholar
• Podolnikova NP, Yakovlev S, Yakubenko VP, Wang X, Gorkun OV, Ugarova TP. The interaction of integrin αIIbβ3 with fibrin occurs through multiple binding sites in the αIIb β-propeller domain. J Biol Chem. 2014;289(4):2371–2383. doi:10.1074/jbc.M113.518126
   PubMed Web of Science ®Google Scholar
• Mammadova-Bach E, Ollivier V, Loyau S, et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood. 2015;126:683–691. doi:10.1182/blood-2015-02-629717
   PubMed Web of Science ®Google Scholar
• Alshehri OM, Hughes CE, Montague S, et al. Fibrin activates GPVI in human and mouse platelets. Blood. 2015;126:1601–1608. doi:10.1182/blood-2015-04-641654
   PubMed Web of Science ®Google Scholar
• Onsalaer M-B, Hardy AT, Wilson C, et al. Fibrin and D-dimer bind to monomeric GPVI. Blood Adv. 2017;1(19):1495–1504. doi:10.1182/bloodadvances.2017007732
   Web of Science ®Google Scholar
• Perrella G, Huang J, Provenzale I, et al. Nonredundant roles of platelet glycoprotein VI and integrin αIIbβ3 in fibrin-mediated microthrombus formation. Arterioscler Thromb Vasc Biol. 2021;41(2):e97–e111. doi:10.1161/ATVBAHA.120.314641
   Web of Science ®Google Scholar
• Nurden AT. Clinical significance of altered collagen receptor functioning in platelets with emphasis on GPVI. Blood Rev. 2019;38:100592. doi:10.1016/j.blre.2019.100592
   PubMed Web of Science ®Google Scholar
• McGregor JL, Clemetson KJ, James E, et al. Glycoproteins of platelet membranes from Glanzmann’s thrombasthenia. A comparison with normal using carbohydrate-specific or protein-specific labeling techniques and high-resolution two-dimensional gel electrophoresis. Eur J Biochem. 1981;116(2):379–388. doi:10.1111/j.1432-1033.1981.tb05346.x
   Google Scholar
• Loroch S, Trabold K, Gambaryan S, et al. Alterations of the platelet proteome in type I Glanzmann thrombasthenia caused by different homozygous delG frameshift mutations in ITGA2B. Thromb Haemost. 2017;117(3):556–569. doi:10.1160/TH16-07-0515
   PubMed Web of Science ®Google Scholar
• Blair TA, Michelson AD, Frelinger AL III. Mass cytometry reveals distinct platelet subtypes in healthy subjects and novel alterations in surface glycoproteins in Glanzmann thrombasthenia. Sci Rep. 2018;8(1):10300. doi:10.1038/s41598-018-28211-5
   PubMed Web of Science ®Google Scholar
• Megy K, Downes K, Simeoni I, et al. Curated disease-causing genes for thrombotic, and platelet disorders; Communication from the SSC of the ISTH. J Thromb Haemost. 2019;17(8):1253–1260. doi:10.1111/jth.14479
   PubMed Web of Science ®Google Scholar
• Ver Donck F, Downes K, Freson K. Strengths and limitations of high-throughput sequencing for the diagnosis of inherited bleeding and platelet disorders. J Thromb Haemost. 2020;18(8):1839–1845. doi:10.1111/jth.14945
   PubMed Web of Science ®Google Scholar
• Buitrago L, Rendon A, Liang Y, et al.,;. αIIbβ3 variants defined by next-generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia. Proc Natl Acad Sci USA. 2015;112:E1898–1907. doi:10.1073/pnas.1422238112
   PubMed Web of Science ®Google Scholar
• Pillois X, Nurden AT. Linkage disequilibrium amongst ITGA2B and ITGB3 gene variants in patients with Glanzmann thrombasthenia confirms that most disease-causing mutations are recent. Br J Haematol. 2016;175(4):686–695. doi:10.1111/bjh.14283
   Web of Science ®Google Scholar
• Di Minno G, Zotz RB, d’Oiron R, et al. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica. 2015;100(8):1031–1037. doi:10.3324/haematol.2014.121475
   Web of Science ®Google Scholar
• Poon MC, Di Minno MN, d’Oiron R, Zotz RB. New insights into the treatment of Glanzmann thrombasthenia. Transfus Med Rev. 2016;30(2):92–99. doi:10.1016/j.tmrv.2016.01.001
   PubMed Web of Science ®Google Scholar
• Al-Battat S, Rand ML, Bouskill V, et al. Glanzmann thrombasthenia platelets compete with transfused platelets, reducing the haemostatic impact of platelet transfusions. Br J Haematol. 2018;81(3):410–413. doi:10.1111/bjh.14623
   Web of Science ®Google Scholar
• Fiore M, Firah N, Pillois X, Nurden P, Heilig R, Nurden AT. Natural history of platelet antibody formation against αIIbβ3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia. 2012;18(3):201–209. doi:10.1111/j.1365-2516.2011.02744.x
   PubMed Web of Science ®Google Scholar
• Nurden AT. Acquired antibodies to αIIbβ3 in Glanzmann thrombasthenia; From transfusion and pregnancy to bone marrow transplants and beyond. Transfus Med Rev. 2018;S0887-7963(18)30037–3. doi:10.1016/j.tmrv.2018.05.002
   Web of Science ®Google Scholar
• Leticée N, Kaplan C, Lémery D. Pregnancy in mother with Glanzmann’s thrombasthenia and isoantibody against GP IIb-IIIa: is there a foetal risk? Eur J Obstet Gynecol Reprod Biol. 2005;121(2):138–142. doi:10.1016/j.ejogrb.2005.02.011
   Web of Science ®Google Scholar
• Santoso S, Wihadmadyatami H, Bakchtoul T, et al. Anti-endothelial αvβ3 antibodies are a major cause of intracranial bleeding in fetal-neonatal alloimmune thrombocytopenia. Arterioscler Thromb Vasc Biol. 2016;36(8):1517–1524. doi:10.1161/ATVBAHA.116.307281
   PubMed Web of Science ®Google Scholar
• Fiore M, Bayat B, Phuangtham R, et al. Immunization against both αIIbβ3 and αvβ3 in Glanzmann thrombasthenia patients carrying the French gypsy mutation. J Thromb Haemost. 2021;19(1):255–261. doi:10.1111/jth.15117
   Web of Science ®Google Scholar
• Guillet B, Bayart S, Pillois X, Nurden P, Caen JP, Nurden AT. A Glanzmann thrombasthenia family associated with a TUBB1-related macrothrombocytopenia. J Thromb Haemost. 2019;17(12):2221. doi:10.1111/jth.14622
   Web of Science ®Google Scholar
• Deshpande R, Shanbhag S, Jadii A, Shetty S. A rare case of Glanzmann’s thrombasthenia and factor VII deficiency due to a combination of pathogenic and non-pathogenic gene variants. Haemophilia. 2020;26(1):e26–e27. doi:10.1111/hae.13898
   Web of Science ®Google Scholar
• Owaidah T, Saleh M, Baz B, et al. Molecular yield of targeted sequencing for Glanzmann thrombasthenia patients. NPJ Genom Med. 2019;4:4. doi:10.1038/s41525-019-0079-6
   Web of Science ®Google Scholar
• Bellucci S, Damaj G, Boval B, et al. Bone marrow transplantation in severe Glanzmann’s thrombasthenia with antiplatelet alloimmunization. Bone Marrow Transplant. 2000;25(3):327–330. doi:10.1038/sj.bmt.1702139
   Web of Science ®Google Scholar
• Flood V, Johnson FL, Boshkov LK, et al. Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia. Pediatr Blood Cancer. 2005;45(7):971–975. doi:10.1002/pbc.20365
   Web of Science ®Google Scholar
• Fang J, Hodivala-Dilke K, Johnson BD, et al. Therapeutic expression of the platelet-specific integrin, αIIbβ3, in a murine model for Glanzmann thrombasthenia. Blood. 2005;106(8):2671–2679. doi:10.1182/blood-2004-12-4619
   Web of Science ®Google Scholar
• Fang J, Jensen ES, Boudreaux MK, et al. Platelet gene therapy improves hemostatic function for integrin αIIbβ3-deficient dogs. Proc Natl Acad Sci USA. 2011;108(23):9583–9588. doi:10.1073/pnas.1016394108
   Web of Science ®Google Scholar
• Sullivan KA, Mills JA, Koukouritaki SB, et al. High-level transgene expression in induced pluripotent stem-cell derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood. 2013;124(5):753–757.
   Web of Science ®Google Scholar
• Hu L, Du L, Zhao Y, et al. Modeling Glanzmann thrombasthenia using patient specific iPSCs and restoring platelet aggregation function by CD41 overexpression. Stem Cell Res. 2017;2:14–20. doi:10.1016/j.scr.2017.02.003
   Web of Science ®Google Scholar
• Zhang N, Zhi H, Curtis BR, et al. CRISPR/Cas9-mediated conversion of human platelet alloantigen allotypes. Blood. 2016;127(6):675–680. doi:10.1182/blood-2015-10-675751
   Web of Science ®Google Scholar
• Engin MMN. Bleeding disorders associated with abnormal platelets: glanzmann thrombasthenia and Bernard-Soulier syndrome. Platelets. 2020. doi:10.5772/intechopen.9329
   Google Scholar